D tumoroid models transform cancer research, accurately reflecting tumor biology and enabling effective drug testing and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

IMP761 is a first-in-class agonist LAG-3 antibody designed to restore balance to the immune system by enhancing the "brake” ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

Bone metastases are at the center of advanced prostate cancer care, with over 90% of patients with metastatic prostate cancer expected to have bone involvement. 1 These metastatic ...